{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T13:23:24Z","timestamp":1791033804600,"version":"4.1.0"},"reference-count":91,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,8,11]],"date-time":"2025-08-11T00:00:00Z","timestamp":1754870400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,8,11]],"date-time":"2025-08-11T00:00:00Z","timestamp":1754870400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100010221","name":"Higher Education Commision, Pakistan","doi-asserted-by":"publisher","award":["20-15729\/NRPU\/R&D\/HEC\/2021 2021"],"award-info":[{"award-number":["20-15729\/NRPU\/R&D\/HEC\/2021 2021"]}],"id":[{"id":"10.13039\/501100010221","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Naunyn-Schmiedeberg's Arch Pharmacol"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1007\/s00210-025-04508-x","type":"journal-article","created":{"date-parts":[[2025,8,11]],"date-time":"2025-08-11T10:26:53Z","timestamp":1754908013000},"page":"47-62","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Repurposing fluoroquinolones as cancer chemosensitizers: a way to overcome cancer therapeutic bottleneck"],"prefix":"10.1007","volume":"399","author":[{"given":"Muhammad","family":"Ishaq","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erum","family":"Zafar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad Faisal","family":"Maqbool","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad","family":"Mansha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad","family":"Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongming","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,8,11]]},"reference":[{"issue":"7","key":"4508_CR1","doi-asserted-by":"crossref","first-page":"1800376","DOI":"10.1002\/ardp.201800376","volume":"352","author":"MA Abdel-Aal","year":"2019","unstructured":"Abdel-Aal MA, Abdel-Aziz SA, Shaykoon MS, Abuo-Rahma GE (2019) Towards anticancer fluoroquinolones: a review article. Arch Pharm 352(7):1800376","journal-title":"Arch Pharm"},{"issue":"105","key":"4508_CR2","doi-asserted-by":"crossref","first-page":"104383","DOI":"10.1016\/j.bioorg.2020.104383","volume":"1","author":"H Ahadi","year":"2020","unstructured":"Ahadi H, Shokrzadeh M, Hosseini-Khah Z, Ghasemian M, Emadi E, Zargari M, Razzaghi-Asl N, Emami S (2020) Synthesis and biological assessment of ciprofloxacin-derived 1, 3, 4-thiadiazoles as anticancer agents. Bioorg Chem 1(105):104383","journal-title":"Bioorg Chem"},{"issue":"5","key":"4508_CR3","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.62110\/sciencein.jist.2025.v13.1112","volume":"13","author":"V Ahlawat","year":"2025","unstructured":"Ahlawat V, Sura K, Khan S, Jakhar R, Dangi M (2025) Repurposing of FDA-approved drugs as potential DNA gyrase inhibitors. J Integr Sci Technol 13(5):1112","journal-title":"J Integr Sci Technol"},{"issue":"296","key":"4508_CR4","doi-asserted-by":"crossref","first-page":"122093","DOI":"10.1016\/j.biomaterials.2023.122093","volume":"1","author":"SO Alhaj-Suliman","year":"2023","unstructured":"Alhaj-Suliman SO, Naguib YW, Wafa EI, Saha S, Ebeid K, Meng X, Mohammed HH, Abuo-Rahma GE, Yang S, Salem AK (2023) A ciprofloxacin derivative with four mechanisms of action overcomes paclitaxel resistance in p53-mutant and MDR1 gene-expressing type II human endometrial cancer. Biomaterials 1(296):122093","journal-title":"Biomaterials"},{"issue":"8","key":"4508_CR5","first-page":"961","volume":"42","author":"N Aoyama","year":"2015","unstructured":"Aoyama N, Asano S, Shingu M, Ueno K, Miyashita M, Hamada H, Aikata H, Kataoka T (2015) Changes in appetite, nutrition, and oxidative stress reaction of cancer patients during chemotherapy. Cancer Chemother 42(8):961\u2013965","journal-title":"Cancer Chemother"},{"issue":"2","key":"4508_CR6","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1002\/ptr.6862","volume":"35","author":"A Ashaq","year":"2021","unstructured":"Ashaq A, Maqbool MF, Maryam A, Khan M, Shakir HA, Irfan M, Qazi JI, Li Y, Ma T (2021) Hispidulin: a novel natural compound with therapeutic potential against human cancers. Phytother Res 35(2):771\u2013789","journal-title":"Phytother Res"},{"issue":"8","key":"4508_CR7","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1007\/s12032-021-01538-2","volume":"38","author":"L Aydemir","year":"2021","unstructured":"Aydemir L, Iplik ES, Ertugrul B, Kasarci G, Atas MN, Ulusan M, Ergen A, Cakmakoglu B (2021) Levofloxacin might be safe to use for OSCC patients. Med Oncol 38(8):87","journal-title":"Med Oncol"},{"issue":"2","key":"4508_CR8","doi-asserted-by":"crossref","first-page":"127","DOI":"10.37201\/req\/143.2023","volume":"37","author":"J Barber\u00e1n","year":"2023","unstructured":"Barber\u00e1n J, de la Cuerda A, Gonz\u00e1lez MI, Aparicio AL, Vinuesa CM, S\u00e1nchez AR, Barber\u00e1n LC (2023) Safety of fluoroquinolones. Rev Esp Quimioter 37(2):127","journal-title":"Rev Esp Quimioter"},{"issue":"118","key":"4508_CR9","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.exer.2013.10.009","volume":"1","author":"M Barot","year":"2014","unstructured":"Barot M, Gokulgandhi MR, Pal D, Mitra AK (2014) In vitro moxifloxacin drug interaction with chemotherapeutics: implications for retinoblastoma management. Exp Eye Res 1(118):61\u201371","journal-title":"Exp Eye Res"},{"issue":"2","key":"4508_CR10","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.ijantimicag.2015.04.008","volume":"46","author":"BL Bearson","year":"2015","unstructured":"Bearson BL, Brunelle BW (2015) Fluoroquinolone induction of phage-mediated gene transfer in multidrug-resistant Salmonella. Int J Antimicrob Agents 46(2):201\u2013204","journal-title":"Int J Antimicrob Agents"},{"issue":"10","key":"4508_CR11","doi-asserted-by":"crossref","first-page":"2194","DOI":"10.3390\/ijms18102194","volume":"18","author":"A Beberok","year":"2017","unstructured":"Beberok A, Wrze\u015bniok D, Szlachta M, Rok J, Rzepka Z, Respondek M, Buszman E (2017) Lomefloxacin induces oxidative stress and apoptosis in COLO829 melanoma cells. Int J Mol Sci 18(10):2194","journal-title":"Int J Mol Sci"},{"issue":"835","key":"4508_CR12","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.ejphar.2018.08.002","volume":"15","author":"A Beberok","year":"2018","unstructured":"Beberok A, Rzepka Z, Respondek M, Rok J, Sierotowicz D, Wrze\u015bniok D (2018) GSH depletion, mitochondrial membrane breakdown, caspase-3\/7 activation and DNA fragmentation in U87MG glioblastoma cells: new insight into the mechanism of cytotoxicity induced by fluoroquinolones. Eur J Pharmacol 15(835):94\u2013107","journal-title":"Eur J Pharmacol"},{"issue":"12","key":"4508_CR13","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1038\/nrclinonc.2015.169","volume":"12","author":"F Bertolini","year":"2015","unstructured":"Bertolini F, Sukhatme VP, Bouche G (2015) Drug repurposing in oncology\u2014patient and health systems opportunities. Nat Rev Clin Oncol 12(12):732\u2013742","journal-title":"Nat Rev Clin Oncol"},{"issue":"3","key":"4508_CR14","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1111\/j.1476-5381.2009.00161.x","volume":"157","author":"LA Bourikas","year":"2009","unstructured":"Bourikas LA, Kolios G, Valatas V, Notas G, Drygiannakis I, Pelagiadis I, Manousou P, Klironomos S, Mouzas IA, Kouroumalis E (2009) Ciprofloxacin decreases survival in HT-29 cells via the induction of TGF-\u03b21 secretion and enhances the anti-proliferative effect of 5-fluorouracil. Br J Pharmacol 157(3):362\u2013370","journal-title":"Br J Pharmacol"},{"issue":"37","key":"4508_CR15","doi-asserted-by":"crossref","first-page":"9404","DOI":"10.1039\/c1dt10674k","volume":"40","author":"R Buchtik","year":"2011","unstructured":"Buchtik R, Tr\u00e1vn\u00ed\u010dek Z, Van\u010do J, Herchel R, Dvo\u0159\u00e1k Z (2011) Synthesis, characterization, DNA interaction and cleavage, and in vitro cytotoxicity of copper (II) mixed-ligand complexes with 2-phenyl-3-hydroxy-4 (1H)-quinolinone. Dalton Trans 40(37):9404\u20139412","journal-title":"Dalton Trans"},{"issue":"3","key":"4508_CR16","first-page":"365","volume":"4","author":"T Chandrasekar","year":"2015","unstructured":"Chandrasekar T, Yang JC, Gao AC, Evans CP (2015) Mechanisms of resistance in castration-resistant prostate cancer (CRPC). Transl Androl Urol 4(3):365","journal-title":"Transl Androl Urol"},{"issue":"22","key":"4508_CR17","doi-asserted-by":"crossref","first-page":"6610","DOI":"10.1158\/0008-5472.CAN-14-1106","volume":"74","author":"S Cornaz-Buros","year":"2014","unstructured":"Cornaz-Buros S, Riggi N, DeVito C, Sarre A, Letovanec I, Provero P, Stamenkovic I (2014) Targeting cancer stem\u2013like cells as an approach to defeating cellular heterogeneity in Ewing sarcoma. Can Res 74(22):6610\u20136622","journal-title":"Can Res"},{"key":"4508_CR18","doi-asserted-by":"crossref","unstructured":"Correia AS, G\u00e4rtner F, Vale N (2021) Drug combination and repurposing for cancer therapy: the example of breast cancer. Heliyon 7(1)","DOI":"10.1016\/j.heliyon.2021.e05948"},{"key":"4508_CR19","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1007\/s10096-014-2296-3","volume":"34","author":"A Dalhoff","year":"2015","unstructured":"Dalhoff A (2015) Antiviral, antifungal, and antiparasitic activities of fluoroquinolones optimized for treatment of bacterial infections: a puzzling paradox or a logical consequence of their mode of action? Eur J Clin Microbiol Infect Dis 34:661\u2013668","journal-title":"Eur J Clin Microbiol Infect Dis"},{"issue":"6","key":"4508_CR20","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/S1473-3099(03)00658-3","volume":"3","author":"A Dalhoff","year":"2003","unstructured":"Dalhoff A, Shalit I (2003) Immunomodulatory effects of quinolones. Lancet Infect Dis 3(6):359\u2013371","journal-title":"Lancet Infect Dis"},{"issue":"2","key":"4508_CR21","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1002\/cac2.12627","volume":"45","author":"X Diao","year":"2025","unstructured":"Diao X, Guo C, Jin Y, Li B, Gao X, Du X, Chen Z, Jo M, Zeng Y, Ding C, Liu W (2025) Cancer situation in China: an analysis based on the global epidemiological data released in 2024. Cancer Commun 45(2):178\u2013197","journal-title":"Cancer Commun"},{"issue":"12","key":"4508_CR22","doi-asserted-by":"crossref","first-page":"2263","DOI":"10.1002\/(SICI)1097-0142(19971215)80:12<2263::AID-CNCR7>3.0.CO;2-V","volume":"80","author":"S Ebisuno","year":"1997","unstructured":"Ebisuno S, Inagaki T, Kohjimoto Y, Ohkawa T (1997) The cytotoxic effects of fleroxacin and ciprofloxacin on transitional cell carcinoma in vitro. Cancer: Interdiscip Int J Am Cancer Soc 80(12):2263\u20137","journal-title":"Cancer: Interdiscip Int J Am Cancer Soc"},{"issue":"1","key":"4508_CR23","first-page":"207","volume":"21","author":"BF El-Rayes","year":"2002","unstructured":"El-Rayes BF, Grignon R, Aslam N, Aranha O, Sarkar FH (2002) Ciprofloxacin inhibits cell growth and synergises the effect of etoposide in hormone resistant prostate cancer cells. Int J Oncol 21(1):207\u2013211","journal-title":"Int J Oncol"},{"issue":"3","key":"4508_CR24","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1159\/000336130","volume":"88","author":"DS Engeler","year":"2012","unstructured":"Engeler DS, Scandella E, Ludewig B, Schmid HP (2012) Ciprofloxacin and epirubicin synergistically induce apoptosis in human urothelial cancer cell lines. Urol Int 88(3):343\u2013349","journal-title":"Urol Int"},{"issue":"8","key":"4508_CR25","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1038\/sj.bjc.6603355","volume":"95","author":"I Fabian","year":"2006","unstructured":"Fabian I, Reuveni D, Levitov A, Halperin D, Priel E, Shalit I (2006) Moxifloxacin enhances antiproliferative and apoptotic effects of etoposide but inhibits its proinflammatory effects in THP-1 and Jurkat cells. Br J Cancer 95(8):1038\u20131046","journal-title":"Br J Cancer"},{"issue":"305","key":"4508_CR26","doi-asserted-by":"crossref","first-page":"120789","DOI":"10.1016\/j.lfs.2022.120789","volume":"15","author":"AC Famurewa","year":"2022","unstructured":"Famurewa AC, Mukherjee AG, Wanjari UR, Sukumar A, Murali R, Renu K, Vellingiri B, Dey A, Gopalakrishnan AV (2022) Repurposing FDA-approved drugs against the toxicity of platinum-based anticancer drugs. Life Sci 15(305):120789","journal-title":"Life Sci"},{"issue":"26","key":"4508_CR27","first-page":"1793","volume":"7","author":"Y Fu","year":"2013","unstructured":"Fu Y, Zhou S, Li D, Zhang YF, Li SS, Li CZ (2013) Ciprofloxacin inhibits proliferation and synergistic effect against hepatocellular carcinoma cancer lines with cisplatin. Afr J Pharm Pharmacol 7(26):1793\u20131801","journal-title":"Afr J Pharm Pharmacol"},{"issue":"3","key":"4508_CR28","doi-asserted-by":"crossref","first-page":"213","DOI":"10.33320\/maced.pharm.bull.2020.66.03.106","volume":"66","author":"V Getova","year":"2020","unstructured":"Getova V, Getov I (2020) Safety limitations of fluoroquinolones\u2019 use. Maced Pharm Bul 66(3):213\u2013214","journal-title":"Maced Pharm Bul"},{"issue":"6","key":"4508_CR29","first-page":"1747","volume":"23","author":"JH Gong","year":"2010","unstructured":"Gong JH, Liu XJ, Shang BY, Chen SZ, Zhen YS (2010) HERG K+ channel related chemosensitivity to sparfloxacin in colon cancer cells. Oncol Rep 23(6):1747\u20131756","journal-title":"Oncol Rep"},{"issue":"1","key":"4508_CR30","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/s43556-024-00239-2","volume":"6","author":"Y Gu","year":"2025","unstructured":"Gu Y, Yang R, Zhang Y, Guo M, Takehiro K, Zhan M, Yang L, Wang H (2025) Molecular mechanisms and therapeutic strategies in overcoming chemotherapy resistance in cancer. Mol Biomed 6(1):2","journal-title":"Mol Biomed"},{"issue":"9","key":"4508_CR31","doi-asserted-by":"crossref","first-page":"4220","DOI":"10.1007\/s12010-022-03960-2","volume":"194","author":"S Gul","year":"2022","unstructured":"Gul S, Maqbool MF, Zheng D, Li Y, Khan M, Ma T (2022) Alpinetin: a dietary flavonoid with diverse anticancer effects. Appl Biochem Biotechnol 194(9):4220\u20134243","journal-title":"Appl Biochem Biotechnol"},{"issue":"2","key":"4508_CR32","doi-asserted-by":"crossref","first-page":"268","DOI":"10.3390\/ijms20020268","volume":"20","author":"P Gupta","year":"2019","unstructured":"Gupta P, Gao HL, Ashar YV, Karadkhelkar NM, Yoganathan S, Chen ZS (2019) Ciprofloxacin enhances the chemosensitivity of cancer cells to ABCB1 substrates. Int J Mol Sci 20(2):268","journal-title":"Int J Mol Sci"},{"issue":"10","key":"4508_CR33","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1288\/00005537-199310000-00001","volume":"103","author":"J Haller","year":"1993","unstructured":"Haller J, Burgess R, Dawson D (1993) Increased cytotoxicity of squamous cell carcinoma of the head and neck by combining cisplatin with VP-16 and ciprofloxacin. Laryngoscope 103(10):1081\u20131083","journal-title":"Laryngoscope"},{"issue":"9","key":"4508_CR34","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1080\/01635581.2020.1803932","volume":"73","author":"SH Hassan","year":"2021","unstructured":"Hassan SH, Gul S, Zahra HS, Maryam A, Shakir HA, Khan M, Irfan M (2021) Alpha solanine: a novel natural bioactive molecule with anticancer effects in multiple human malignancies. Nutr Cancer 73(9):1541\u20131552","journal-title":"Nutr Cancer"},{"issue":"4","key":"4508_CR35","doi-asserted-by":"crossref","first-page":"e10186","DOI":"10.1371\/journal.pone.0010186","volume":"5","author":"RE Hawtin","year":"2010","unstructured":"Hawtin RE, Stockett DE, Byl JA, McDowell RS, Tan N, Arkin MR, Conroy A, Yang W, Osheroff N, Fox JA (2010) Voreloxin is an anticancer quinolone derivative that intercalates DNA and poisons topoisomerase II. PLoS ONE 5(4):e10186","journal-title":"PLoS ONE"},{"issue":"1","key":"4508_CR36","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1007\/s12672-022-00541-x","volume":"13","author":"X He","year":"2022","unstructured":"He X, Yao Q, Fan D, You Y, Lian W, Zhou Z, Duan L (2022) Combination of levofloxacin and cisplatin enhances anticancer efficacy via co-regulation of eight cancer-associated genes. Discov Oncol 13(1):76","journal-title":"Discov Oncol"},{"key":"4508_CR37","doi-asserted-by":"crossref","unstructured":"He X, Yao Q, Song ZY, Fan D, You YT, Lian WJ, Zhou ZP, Duan L (2019) Levofloxacin can greatly influence clinical practice of cancer treatment: it has broad-spectrum anticancer activity and synergistically enhance conventional chemotherapy. Available at SSRN 3426094","DOI":"10.2139\/ssrn.3426094"},{"issue":"3","key":"4508_CR38","first-page":"751","volume":"23","author":"C Herold","year":"2003","unstructured":"Herold C, Ganslmayer M, Ocker M, Blauberger S, Zopf S, Hahn EG, Schuppan D (2003) Overadditive anti-proliferative and pro-apoptotic effects of a combination therapy on colorectal carcinoma cells. Int J Oncol 23(3):751\u2013756","journal-title":"Int J Oncol"},{"issue":"3","key":"4508_CR39","doi-asserted-by":"publisher","first-page":"1769","DOI":"10.3390\/cancers6031769","volume":"6","author":"G Housman","year":"2014","unstructured":"Housman G, Byler S, Heerboth S, Lapinska K, Longacre M, Snyder N, Sarkar S (2014) Cancers 6(3):1769\u20131792. https:\/\/doi.org\/10.3390\/cancers6031769","journal-title":"Cancers"},{"issue":"23","key":"4508_CR40","doi-asserted-by":"crossref","first-page":"25203","DOI":"10.1021\/acsomega.4c02882","volume":"9","author":"MA Ibrahim","year":"2024","unstructured":"Ibrahim MA, Rady AS, Sidhom PA, Sayed SR, Ibrahim KE, Awad AM, Shoeib T, Mohamed LA (2024) A comparative DFT investigation of the adsorption of temozolomide anticancer drug over beryllium oxide and boron nitride nanocarriers. ACS Omega 9(23):25203\u201325214","journal-title":"ACS Omega"},{"issue":"4","key":"4508_CR41","doi-asserted-by":"crossref","first-page":"26","DOI":"10.3390\/antibiotics6040026","volume":"6","author":"T Idowu","year":"2017","unstructured":"Idowu T, Schweizer F (2017) Ubiquitous nature of fluoroquinolones: the oscillation between antibacterial and anticancer activities. Antibiotics 6(4):26","journal-title":"Antibiotics"},{"key":"4508_CR42","doi-asserted-by":"crossref","first-page":"881","DOI":"10.3389\/fphar.2019.00881","volume":"10","author":"E Izadi","year":"2019","unstructured":"Izadi E, Afshan G, Patel RP, Rao VM, Liew KB, Meor Mohd Affandi MM, Kifli N, Suleiman A, Lee KS, Sarker MM, Zaidi ST (2019) Levofloxacin: insights into antibiotic resistance and product quality. Front Pharmacol 10:881","journal-title":"Front Pharmacol"},{"issue":"13","key":"4508_CR43","doi-asserted-by":"crossref","first-page":"3056","DOI":"10.3390\/cancers14133056","volume":"14","author":"K Ja\u0142brzykowska","year":"2022","unstructured":"Ja\u0142brzykowska K, Chrzanowska A, Roszkowski P, Struga M (2022) The new face of a well-known antibiotic: a review of the anticancer activity of enoxacin and its derivatives. Cancers 14(13):3056","journal-title":"Cancers"},{"issue":"13","key":"4508_CR44","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1007\/s40265-016-0614-z","volume":"76","author":"GC Jamieson","year":"2016","unstructured":"Jamieson GC, Fox JA, Poi M, Strickland SA (2016) Molecular and pharmacologic properties of the anticancer quinolone derivative vosaroxin: a new therapeutic agent for acute myeloid leukemia. Drugs 76(13):1245\u20131255","journal-title":"Drugs"},{"issue":"11","key":"4508_CR45","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1007\/s10495-019-01564-6","volume":"24","author":"E Jasek-Gajda","year":"2019","unstructured":"Jasek-Gajda E, Jurkowska H, Jasi\u0144ska M, Litwin JA, Lis GJ (2019) Combination of ERK2 inhibitor VX-11e and voreloxin synergistically enhances anti-proliferative and pro-apoptotic effects in leukemia cells. Apoptosis 24(11):849\u2013861","journal-title":"Apoptosis"},{"issue":"1","key":"4508_CR46","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/S0090-4295(99)00064-3","volume":"54","author":"AM Kamat","year":"1999","unstructured":"Kamat AM, DeHaven JI, Lamm DL (1999) Quinolone antibiotics: a potential adjunct to intravesical chemotherapy for bladder cancer. Urology 54(1):56\u201361","journal-title":"Urology"},{"key":"4508_CR47","doi-asserted-by":"crossref","unstructured":"Kassab AE, Gomaa RM, Gedawy EM (2024) Drug repurposing of fluoroquinolones as anticancer agents in 2023. RSC Advances 14(50):37114\u201330","DOI":"10.1039\/D4RA03571B"},{"issue":"5","key":"4508_CR48","first-page":"561","volume":"65","author":"AK Khaleel","year":"2022","unstructured":"Khaleel AK, Shaari RB, Nawi MA, Al-Yassiri AM (2022) Toxicological aspects of fluoroquinolones administration: a literature review. Egypt J Chem 65(5):561\u2013569","journal-title":"Egypt J Chem"},{"issue":"2","key":"4508_CR49","doi-asserted-by":"crossref","first-page":"205","DOI":"10.17582\/journal.pujz\/2018.33.2.205.209","volume":"33","author":"M Khan","year":"2018","unstructured":"Khan M (2018) Proscillaradin A: from cardiac glycosides to cancer therapeutics. Punjab Univ J Zool 33(2):205\u2013209","journal-title":"Punjab Univ J Zool"},{"issue":"1","key":"4508_CR50","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1128\/AAC.45.1.48-51.2001","volume":"45","author":"AA Khan","year":"2001","unstructured":"Khan AA, Slifer TR, Araujo FG, Remington JS (2001) Activity of gatifloxacin alone or in combination with pyrimethamine or gamma interferon against Toxoplasma gondii. Antimicrob Agents Chemother 45(1):48\u201351","journal-title":"Antimicrob Agents Chemother"},{"key":"4508_CR51","doi-asserted-by":"crossref","unstructured":"Krug LM, Crawford J, Ettinger DS, Shapiro GI, Spigel D, Reiman T, Adelman DC (2011) Phase II multicenter trial of voreloxin as second-line therapy in chemotherapy-sensitive or refractory small cell lung cancer. J Thor Oncol 6(2):384\u2013386","DOI":"10.1097\/JTO.0b013e318200e509"},{"issue":"3","key":"4508_CR52","doi-asserted-by":"crossref","first-page":"422","DOI":"10.4085\/1062-6050-49.2.09","volume":"49","author":"T Lewis","year":"2014","unstructured":"Lewis T, Cook J (2014) Fluoroquinolones and tendinopathy: a guide for athletes and sports clinicians and a systematic review of the literature. J Athl Train 49(3):422\u2013427","journal-title":"J Athl Train"},{"issue":"1","key":"4508_CR53","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.emc.2013.09.002","volume":"32","author":"Z Livshits","year":"2014","unstructured":"Livshits Z, Rao RB, Smith SW (2014) An approach to chemotherapy-associated toxicity. Emergency Medicine Clinics 32(1):167\u2013203","journal-title":"Emergency Medicine Clinics"},{"issue":"1","key":"4508_CR54","doi-asserted-by":"crossref","first-page":"109724","DOI":"10.1016\/j.cclet.2024.109724","volume":"36","author":"X Luo","year":"2025","unstructured":"Luo X, Wu Y, Zhang X, Tang M, Ju F, Qin Z, Duns GJ, Zhang WD, Qin JJ, Luan X (2025) Peptide-based strategies for overcoming multidrug-resistance in cancer therapy. Chin Chem Lett 36(1):109724","journal-title":"Chin Chem Lett"},{"issue":"5","key":"4508_CR55","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1111\/j.1442-2042.2007.01750.x","volume":"14","author":"SI Maeda","year":"2007","unstructured":"Maeda SI, Tamaki M, Kubota Y, Nguyen PB, Yasuda M, Deguchi T (2007) Treatment of men with urethritis negative for Neisseria gonorrhoeae, Chlamydia trachomatis, Mycoplasma genitalium, Mycoplasma hominis, Ureaplasma parvum and Ureaplasma urealyticum. Int J Urol 14(5):422\u2013425","journal-title":"Int J Urol"},{"issue":"13","key":"4508_CR56","doi-asserted-by":"crossref","first-page":"1354","DOI":"10.2174\/1389450121666200621193355","volume":"21","author":"PP Majalekar","year":"2020","unstructured":"Majalekar PP, Shirote PJ (2020) Fluoroquinolones: blessings or curses. Curr Drug Targets 21(13):1354\u20131370","journal-title":"Curr Drug Targets"},{"issue":"4","key":"4508_CR57","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1111\/cas.14318","volume":"111","author":"T Masuda","year":"2020","unstructured":"Masuda T, Tsuruda Y, Matsumoto Y, Uchida H, Nakayama KI, Mimori K (2020) Drug repositioning in cancer: the current situation in Japan. Cancer Sci 111(4):1039\u20131046","journal-title":"Cancer Sci"},{"issue":"6","key":"4508_CR58","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1016\/j.urology.2009.03.006","volume":"74","author":"T Nishikawa","year":"2009","unstructured":"Nishikawa T, Kohjimoto Y, Nishihata M, Ebisuno S, Hara I (2009) Synergistic antitumor effects of fleroxacin with 5-fluorouracil in vitro and in vivo for bladder cancer cell lines. Urology 74(6):1370\u20131376","journal-title":"Urology"},{"issue":"7","key":"4508_CR59","first-page":"E1","volume":"32","author":"LM Pallo-Zimmerman","year":"2010","unstructured":"Pallo-Zimmerman LM, Byron JK, Graves TK (2010) Fluoroquinolones: then and now. Compend Contin Educ Vet 32(7):E1-9","journal-title":"Compend Contin Educ Vet"},{"issue":"3","key":"4508_CR60","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1038\/nrd3078","volume":"9","author":"SM Paul","year":"2010","unstructured":"Paul SM, Mytelka DS, Dunwiddie CT, Persinger CC, Munos BH, Lindborg SR, Schacht AL (2010) How to improve R&D productivity: the pharmaceutical industry\u2019s grand challenge. Nat Rev Drug Discovery 9(3):203\u2013214","journal-title":"Nat Rev Drug Discovery"},{"issue":"1","key":"4508_CR61","doi-asserted-by":"crossref","first-page":"e0317281","DOI":"10.1371\/journal.pone.0317281","volume":"20","author":"S Phuagkhaopong","year":"2025","unstructured":"Phuagkhaopong S, Sukwattanasombat J, Suknuntha K, Power C, Wonganan P, Vivithanaporn P (2025) Anti-inflammatory effects of moxifloxacin and levofloxacin on cadmium-activated human astrocytes: inhibition of proinflammatory cytokine release, TLR4\/STAT3, and ERK\/NF-\u03baB signaling pathway. PLoS ONE 20(1):e0317281","journal-title":"PLoS ONE"},{"issue":"6","key":"4508_CR62","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1093\/jac\/dki359","volume":"56","author":"T Piercy","year":"2005","unstructured":"Piercy T, Steward J, Lever MS, Brooks TJ (2005) In vivo efficacy of fluoroquinolones against systemic tularaemia infection in mice. J Antimicrob Chemother 56(6):1069\u20131073","journal-title":"J Antimicrob Chemother"},{"key":"4508_CR63","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1007\/s00280-008-0892-6","volume":"64","author":"AC Pinto","year":"2009","unstructured":"Pinto AC, Moreira JN, Sim\u00f5es S (2009) Ciprofloxacin sensitizes hormone-refractory prostate cancer cell lines to doxorubicin and docetaxel treatment on a schedule-dependent manner. Cancer Chemother Pharmacol 64:445\u2013454","journal-title":"Cancer Chemother Pharmacol"},{"key":"4508_CR64","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1007\/s00280-010-1315-z","volume":"67","author":"AC Pinto","year":"2011","unstructured":"Pinto AC, \u00c2ngelo S, Moreira JN, Sim\u00f5es S (2011) Schedule treatment design and quantitative in vitro evaluation of chemotherapeutic combinations for metastatic prostate cancer therapy. Cancer Chemother Pharmacol 67:275\u2013284","journal-title":"Cancer Chemother Pharmacol"},{"issue":"1","key":"4508_CR65","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1021\/cb300648v","volume":"8","author":"Y Pommier","year":"2013","unstructured":"Pommier Y (2013) Drugging topoisomerases: lessons and challenges. ACS Chem Biol 8(1):82\u201395","journal-title":"ACS Chem Biol"},{"issue":"8","key":"4508_CR66","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.1021\/acs.chemrestox.9b00204","volume":"32","author":"L Qi","year":"2019","unstructured":"Qi L, Luo Q, Zhang Y, Jia F, Zhao Y, Wang F (2019) Advances in toxicological research of the anticancer drug cisplatin. Chem Res Toxicol 32(8):1469\u20131486","journal-title":"Chem Res Toxicol"},{"issue":"6","key":"4508_CR67","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1016\/j.bcp.2007.11.014","volume":"75","author":"D Reuveni","year":"2008","unstructured":"Reuveni D, Halperin D, Shalit I, Priel E, Fabian I (2008) Quinolones as enhancers of camptothecin-induced cytotoxic and anti-topoisomerase I effects. Biochemical Pharmacology 75(6):1272\u20131281","journal-title":"Biochemical pharmacology"},{"issue":"8","key":"4508_CR68","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1016\/j.bcp.2009.12.001","volume":"79","author":"D Reuveni","year":"2010","unstructured":"Reuveni D, Halperin D, Fabian I, Tsarfaty G, Askenasy N, Shalit I (2010a) Moxifloxacin increases anti-tumor and anti-angiogenic activity of irinotecan in human xenograft tumors. Biochem Pharmacol 79(8):1100\u20131107","journal-title":"Biochem Pharmacol"},{"issue":"2","key":"4508_CR69","first-page":"463","volume":"37","author":"D Reuveni","year":"2010","unstructured":"Reuveni D, Halperin D, Shalit I, Priel E, Fabian I (2010b) Moxifloxacin enhances etoposide-induced cytotoxic, apoptotic and anti-topoisomerase II effects in a human colon carcinoma cell line.\u00a0Int J Oncol\u00a037(2):463\u2013471","journal-title":"International journal of oncology"},{"issue":"2","key":"4508_CR70","first-page":"128","volume":"12","author":"R Rustomjee","year":"2008","unstructured":"Rustomjee R, Lienhardt C, Kanyok T, Davies GR, Levin J, Mthiyane T, Reddy C, Sturm AW, Sirgel FA, Allen J, Coleman DJ (2008) A Phase II study of the sterilising activities of ofloxacin, gatifloxacin and moxifloxacin in pulmonary tuberculosis. Int J Tuberc Lung Dis 12(2):128\u2013138","journal-title":"Int J Tuberc Lung Dis"},{"issue":"6","key":"4508_CR71","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1080\/13543776.2021.1879051","volume":"31","author":"A Selas","year":"2021","unstructured":"Selas A, Martin-Encinas E, Fuertes M, Masdeu C, Rubiales G, Palacios F, Alonso C (2021) A patent review of topoisomerase I inhibitors (2016\u2013present). Expert Opin Ther Pat 31(6):473\u2013508","journal-title":"Expert Opin Ther Pat"},{"issue":"17","key":"4508_CR72","doi-asserted-by":"crossref","first-page":"100296","DOI":"10.1016\/j.mtchem.2020.100296","volume":"1","author":"PC Sharma","year":"2020","unstructured":"Sharma PC, Goyal R, Sharma A, Sharma D, Saini N, Rajak H, Sharma S, Thakur VK (2020) Insights on fluoroquinolones in cancer therapy: chemistry and recent developments. Mater Today Chem 1(17):100296","journal-title":"Mater Today Chem"},{"issue":"5","key":"4508_CR73","doi-asserted-by":"crossref","first-page":"2606","DOI":"10.3892\/or.2016.4680","volume":"35","author":"S Shi","year":"2016","unstructured":"Shi S, Tan P, Yan B, Gao R, Zhao J, Wang J, Guo J, Li N, Ma Z (2016) ER stress and autophagy are involved in the apoptosis induced by cisplatin in human lung cancer cells. Oncol Rep 35(5):2606\u20132614","journal-title":"Oncol Rep"},{"issue":"4","key":"4508_CR74","doi-asserted-by":"crossref","first-page":"1762","DOI":"10.3390\/molecules28041762","volume":"28","author":"Z Shi","year":"2023","unstructured":"Shi Z, Zhang J, Tian L, Xin L, Liang C, Ren X, Li M (2023) A comprehensive overview of the antibiotics approved in the last two decades: retrospects and prospects. Molecules 28(4):1762","journal-title":"Molecules"},{"issue":"137","key":"4508_CR75","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.rvsc.2021.04.031","volume":"1","author":"A Sitovs","year":"2021","unstructured":"Sitovs A, Sartini I, Giorgi M (2021) Levofloxacin in veterinary medicine: a literature review. Res Vet Sci 1(137):111\u2013126","journal-title":"Res Vet Sci"},{"issue":"2","key":"4508_CR76","first-page":"130","volume":"24","author":"S Sivapragasam","year":"2025","unstructured":"Sivapragasam S (2025) The emerging role of (p) ppGpp in DNA repair and associated bacterial survival against fluoroquinolones. Gene Expr 24(2):130\u2013138","journal-title":"Gene Expr"},{"key":"4508_CR77","doi-asserted-by":"crossref","first-page":"747","DOI":"10.2165\/00003495-200161060-00004","volume":"61","author":"A Smith","year":"2001","unstructured":"Smith A, Pennefather PM, Kaye SB, Hart CA (2001) Fluoroquinolones: place in ocular therapy. Drugs 61:747\u2013761","journal-title":"Drugs"},{"issue":"5","key":"4508_CR78","doi-asserted-by":"crossref","first-page":"548","DOI":"10.4161\/epi.24519","volume":"8","author":"EJ Sousa","year":"2013","unstructured":"Sousa EJ, Graca I, Baptista T, Vieira FQ, Palmeira C, Henrique R, Jeronimo C (2013) Enoxacin inhibits growth of prostate cancer cells and effectively restores microRNA processing. Epigenetics 8(5):548\u2013558","journal-title":"Epigenetics"},{"key":"4508_CR79","doi-asserted-by":"crossref","unstructured":"Tom\u00e9 AM, Filipe A (2011) Quinolones: review of psychiatric and neurological adverse reactions. Drug Safety","DOI":"10.2165\/11587280-000000000-00000"},{"issue":"8","key":"4508_CR80","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/j.trecan.2017.06.007","volume":"3","author":"C Verbaanderd","year":"2017","unstructured":"Verbaanderd C, Meheus L, Huys I, Pantziarka P (2017) Repurposing drugs in oncology: next steps. Trends in Cancer 3(8):543\u2013546","journal-title":"Trends in Cancer"},{"issue":"111","key":"4508_CR81","first-page":"20","volume":"15","author":"Z Wang","year":"2020","unstructured":"Wang Z, Chen J, Little N, Lu J (2020) Self-assembling prodrug nanotherapeutics for synergistic tumor targeted drug delivery. Acta Biomater 15(111):20\u201328","journal-title":"Acta Biomater"},{"key":"4508_CR82","doi-asserted-by":"crossref","unstructured":"Wu P, Han J, Gong Y, Liu C, Yu H, Xie N (2022) Nanoparticle-based drug delivery systems targeting tumor microenvironment for cancer immunotherapy resistance: current advances and applications. Pharmaceutics 14(10):1990","DOI":"10.3390\/pharmaceutics14101990"},{"issue":"10","key":"4508_CR83","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.7150\/ijbs.24612","volume":"14","author":"H Xue","year":"2018","unstructured":"Xue H, Li J, Xie H, Wang Y (2018) Review of drug repositioning approaches and resources. Int J Biol Sci 14(10):1232","journal-title":"Int J Biol Sci"},{"issue":"10","key":"4508_CR84","doi-asserted-by":"crossref","first-page":"e47796","DOI":"10.1371\/journal.pone.0047796","volume":"7","author":"V Yadav","year":"2012","unstructured":"Yadav V, Sultana S, Yadav J, Saini N (2012) Gatifloxacin induces S and G2-phase cell cycle arrest in pancreatic cancer cells via p21\/p27\/p53. PLoS ONE 7(10):e47796","journal-title":"PLoS ONE"},{"issue":"1","key":"4508_CR85","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1186\/s12885-015-1560-y","volume":"15","author":"V Yadav","year":"2015","unstructured":"Yadav V, Varshney P, Sultana S, Yadav J, Saini N (2015) Moxifloxacin and ciprofloxacin induces S-phase arrest and augments apoptotic effects of cisplatin in human pancreatic cancer cells via ERK activation. BMC Cancer 15(1):581","journal-title":"BMC Cancer"},{"issue":"7","key":"4508_CR86","doi-asserted-by":"crossref","first-page":"193","DOI":"10.3389\/fmolb.2020.00193","volume":"20","author":"Y Yao","year":"2020","unstructured":"Yao Y, Zhou Y, Liu L, Xu Y, Chen Q, Wang Y, Wu S, Deng Y, Zhang J, Shao A (2020) Nanoparticle-based drug delivery in cancer therapy and its role in overcoming drug resistance. Front Mol Biosci 20(7):193","journal-title":"Front Mol Biosci"},{"issue":"6","key":"4508_CR87","doi-asserted-by":"crossref","first-page":"e70034","DOI":"10.1111\/cbdd.70034","volume":"104","author":"J Yin","year":"2024","unstructured":"Yin J, Jia P, Qu X, Han Z, Yao L, Wang S, Gao J (2024) Discovery of voreloxin as a dual-selective stabilizer for c-Myc\/Bcl-2 G-quadruplexes in leukemia. Chem Biol Drug des 104(6):e70034","journal-title":"Chem Biol Drug des"},{"issue":"18","key":"4508_CR88","doi-asserted-by":"crossref","first-page":"5649","DOI":"10.1021\/jm900469e","volume":"52","author":"QD You","year":"2009","unstructured":"You QD, Li ZY, Huang CH, Yang Q, Wang XJ, Guo QL, Chen XG, He XG, Li TK, Chern JW (2009) Discovery of a novel series of quinolone and naphthyridine derivatives as potential topoisomerase I inhibitors by scaffold modification. J Med Chem 52(18):5649\u20135661","journal-title":"J Med Chem"},{"issue":"4","key":"4508_CR89","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1016\/j.bbrc.2016.02.072","volume":"471","author":"M Yu","year":"2016","unstructured":"Yu M, Li R, Zhang J (2016) Repositioning of antibiotic levofloxacin as a mitochondrial biogenesis inhibitor to target breast cancer. Biochem Biophys Res Commun 471(4):639\u2013645","journal-title":"Biochem Biophys Res Commun"},{"issue":"2","key":"4508_CR90","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1002\/bab.2150","volume":"69","author":"E Zafar","year":"2022","unstructured":"Zafar E, Maqbool MF, Iqbal A, Maryam A, Shakir HA, Irfan M, Khan M, Li Y, Ma T (2022) A comprehensive review on anticancer mechanism of bazedoxifene. Biotechnol Appl Biochem 69(2):767\u2013782","journal-title":"Biotechnol Appl Biochem"},{"key":"4508_CR91","unstructured":"Zandi A, MOINI ZT, Ziai SA, Khazaei PY, HAJI MH (2017) The synergistic effects of the combination of ciprofloxacin and temozolomide on human glioblastoma A-172 cell line"}],"container-title":["Naunyn-Schmiedeberg's Archives of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00210-025-04508-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00210-025-04508-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00210-025-04508-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T22:08:16Z","timestamp":1771538896000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00210-025-04508-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,11]]},"references-count":91,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["4508"],"URL":"https:\/\/doi.org\/10.1007\/s00210-025-04508-x","relation":{},"ISSN":["0028-1298","1432-1912"],"issn-type":[{"value":"0028-1298","type":"print"},{"value":"1432-1912","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,11]]},"assertion":[{"value":"30 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 August 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interest"}}]}}